(Q37109097)

18 August 2017

1 reference

title

Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry (English)

1 reference

18 August 2017

1 reference

1 reference

1 reference

David W Hedley

1

0 references

author name string

Sue Chow

series ordinal

2

1 reference

18 August 2017

Charles Goolsby

series ordinal

3

1 reference

18 August 2017

T Vincent Shankey

series ordinal

4

1 reference

18 August 2017

language of work or name

English

0 references

publication date

1 January 2008

1 reference

18 August 2017

published in

Toxicologic Pathology

1 reference

18 August 2017

volume

36

1 reference

18 August 2017

issue

1

1 reference

18 August 2017

page(s)

133-139

1 reference

describes a project that uses

18 August 2017

1 reference

Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

Constitutive phosphorylation of the S6 ribosomal protein via mTOR and ERK signaling in the peripheral blasts of acute leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

Measurement of MAP kinase activation by flow cytometry using phospho-specific antibodies to MEK and ERK: potential for pharmacodynamic monitoring of signal transduction inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

The biochemical basis of an all-or-none cell fate switch in Xenopus oocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

Single cell profiling of potentiated phospho-protein networks in cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

Immunoreactivity of Stat5 phosphorylated on tyrosine as a cell-based measure of Bcr/Abl kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

21 January 2018

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0192623307310952

21 January 2018

Identifiers

DOI

10.1177/0192623307310952

1 reference

18 August 2017

1 reference